How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Antibodies Contract Manufacturing Market
- By Antibody Type: Monoclonal Antibodies (mAbs), Polyclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates (ADCs), Recombinant Antibodies
- By Production Technology: Mammalian Cell Culture, Microbial Fermentation, Transgenic Systems, Plant-based Expression Systems, Yeast Expression Systems
- By Service Type: Process Development, Analytical and Characterization Services, Upstream Manufacturing, Downstream Purification, Formulation and Fill-Finish
- By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic and Research Institutes, Contract Research Organizations (CROs), Diagnostic Companies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Monoclonal Antibodies (mAbs) leads By Antibody Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 13 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 277 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 13 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Antibodies Contract Manufacturing Market report
A complete, evidence-based study - 11 chapters and 116 sections covering market size, segmentation across 4 axes, regional analysis and 13 company profiles, forecast to 2033.
Segmentation covered
Antibody Type 5
Production Technology 5
Service Type 5
End-User 5
Companies profiled
Lonza Group AG
Samsung Biologics
Catalent Inc.
WuXi Biologics
Sartorius AG
FUJIFILM Diosynth Biotechnologies
Boehringer Ingelheim BioXcellence
AGC Biologics
Cytovance Biologics
Sandoz (a Novartis division)
KBI Biopharma
Boehringer Ingelheim
+1 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
13 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Lonza Group AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Samsung Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Catalent Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →WuXi Biologics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sartorius AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →FUJIFILM Diosynth Biotechnologies
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.184 →Boehringer Ingelheim BioXcellence
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →AGC Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Cytovance Biologics
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Sandoz (a Novartis division)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →KBI Biopharma
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.214 →Boehringer Ingelheim
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.220 →Siegfried Holding AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$7,487M by 2033 · 10.6% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Monoclonal Antibodies (mAbs)54.6
- Polyclonal Antibodies6.6
- Bispecific Antibodies9.9
- Antibody-Drug Conjugates (ADCs)12.8
- Recombinant Antibodies16.0
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,106M → $2,359M · 9.9%
Europe$771.2M → $1,565M · 9.2%
Asia Pacific$704.1M → $1,598M · 10.8%
Latin America$435.9M → $976.6M · 10.6%
Middle East and Africa$335.3M → $800.6M · 11.5%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.512026
10.532027
10.542028
10.552029
10.562030
10.582031
10.582032
10.592033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Lonza Group AG16.9
- Samsung Biologics20.1
- Catalent Inc.12.9
- WuXi Biologics6.6
- Sartorius AG6.0
- FUJIFILM Diosynth Biotechnologies9.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Antibody Type17.3%
Production Technology24.8%
Service Type31.7%
End-User26.2%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.3
- Europe21.4
- Asia Pacific21.9
- Latin America13.4
- Middle East and Africa11.0
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Lonza Group AG | 96 | 96 | 85 | 85 | 80 | 83 | 88 |
| Samsung Biologics | 68 | 86 | 90 | 78 | 86 | 91 | 83 |
| Catalent Inc. | 81 | 87 | 87 | 70 | 79 | 66 | 78 |
| WuXi Biologics | 67 | 74 | 60 | 69 | 71 | 58 | 67 |
| Sartorius AG | 62 | 63 | 56 | 65 | 53 | 52 | 59 |
| FUJIFILM Diosynth Biotechnologies | 62 | 62 | 46 | 67 | 67 | 67 | 62 |
| Boehringer Ingelheim BioXcellence | 53 | 44 | 62 | 46 | 60 | 41 | 51 |
| AGC Biologics | 39 | 43 | 41 | 54 | 54 | 56 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Lonza Group AG
- Samsung Biologics
- Catalent Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Lonza Group AG | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Samsung Biologics | ◐ | ✓ | ✓ | ✓ | ◐ | ✓ |
| Catalent Inc. | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| WuXi Biologics | ✓ | ✓ | ◐ | ◐ | ◐ | ◐ |
| Sartorius AG | − | ◐ | ◐ | ◐ | ◐ | ◐ |
| FUJIFILM Diosynth Biotechnologies | ◐ | ◐ | − | ◐ | − | ◐ |
| Boehringer Ingelheim BioXcellence | − | − | ◐ | ◐ | − | − |
| AGC Biologics | − | − | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Lonza Group AG88
2Samsung Biologics83
3Catalent Inc.78
4WuXi Biologics67
5FUJIFILM Diosynth Biotechnologies62
6Sartorius AG59
7Boehringer Ingelheim BioXcellence51
8AGC Biologics48
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Lonza Group AGSamsung BiologicsCatalent Inc.
Challenger1
Strong scale, closing on the leaders.
WuXi Biologics
Contender2
Focused players with pockets of strength.
Sartorius AGFUJIFILM Diosynth Biotechnologies
Niche2
Specialists in a single segment or region.
Boehringer Ingelheim BioXcellenceAGC Biologics
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Antibody Type in North America, then scale across Antibodies Contract Manufacturing Market — a $65M beachhead inside a $1.02B market.
Beachhead (SOM)$65Mobtainable near-term
Serviceable (SAM)$389Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion88 fit
Monoclonal Antibodies (mAbs)
Best fit — highest urgency & budget in Antibody Type.
Economic buyer76 fit
Polyclonal Antibodies
Strong fit — clear ROI and a fast path to value.
End user64 fit
Bispecific Antibodies
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Antibody Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Production Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Service Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel29%
Digital / self-serve18%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Antibody Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Antibodies Contract Manufacturing Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified38%
Sales qualified25%
Evaluation15%
Closed-won6%
$11.7KCAC
$58KLTV
5.0:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Antibodies Contract Manufacturing Market is a resilient opportunity — $1.15B by 2033, compounding at 5.2%.
TAM · 2025$765Mtoday
TAM · 2033$1.15Bforecast
CAGR5.2%2027–2033
Cumulative$8.50Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$1.15BTotal addressable market
SAM$395MServiceable available market
SOM$70MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →5.2% CAGR
Demand compounds through 2033, outpacing GDP across Antibody Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Antibody Type moving from early to mainstream — durable secular demand.
Consolidation upside
13+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$1.15BLarge & growingTAM by 2033 at 5.2% CAGR
$395MServiceable nowreachable with today’s model
$70MBeachhead winobtainable near-term share
13+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$894MBear3.4% CAGR
$1.15BBase5.2% CAGR
$1.47BBull6.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Production Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Antibodies Contract Manufacturing Market — a $1.78B market by 2033. Plan: grow share from 10.5% to 16.6%.
Market size · 2033$1.78Btotal addressable
Market CAGR4.9%2027–2033
Target share16.6%from 10.5% today
Revenue ambition$295Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.5% | 16.6% | On track |
| Revenue | $171M | $295M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.4% | 38.4% | Ahead |
| Customer retention | 84.2% | 93.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Antibody Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Production Technology capability
A defensible second engine — invest in Production Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Antibody Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Production Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $35M capacity & capability investment
- Greenlight bolt-on M&A in Production Technology
- Authorise North America expansion plan
- Fund R&D program for Antibody Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossBehind
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Antibodies Contract Manufacturing Market conversation — a $2.02B market you can size, segment and defend in minutes.
Market size · 2033$2.02Btotal opportunity
Growth9.0%CAGR to 2033
Addressable buyers1,119+accounts in scope
Typical ROI6.4×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Antibody Type
Goal Grow share in Antibody Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.4×return on cost, year one
< 3 mopayback period
$78K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
13+players profiled in this market
Coverage includes
Lonza Group AGSamsung BiologicsCatalent Inc.WuXi BiologicsSartorius AGFUJIFILM Diosynth BiotechnologiesBoehringer Ingelheim BioXcellenceAGC Biologics+5 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Antibodies Contract Manufacturing Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Antibodies Contract Manufacturing Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Automatic Home Blood Pressure Monitors Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportAntibodies and Antigens to Cardiovascular Biomarkers Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportGastroenterology Devices Market
Market size, share, segmentation and regional forecast.
$5.0B market · 2025 base year
View reportMetallic Implants Market
Market size, share, segmentation and regional forecast.
$4.3B market · 2025 base year
View reportProsthetic Ceramic Fillers Market
Market size, share, segmentation and regional forecast.
$4.2B market · 2025 base year
View reportGas Flow Analyzers Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportLaparoscopic Surgical Instruments Market
Market size, share, segmentation and regional forecast.
$3.2B market · 2025 base year
View reportAnesthetic Analyzers Market
Market size, share, segmentation and regional forecast.
$320M market · 2025 base year
View reportFractional Exhaled Nitric Oxide Detector Market
Market size, share, segmentation and regional forecast.
$837M market · 2025 base year
View reportAnti-blue Ray Myopia Lenses Market
Market size, share, segmentation and regional forecast.
$981M market · 2025 base year
View report3D Printed Dentures Market
Market size, share, segmentation and regional forecast.
$926M market · 2025 base year
View reportExhaled Nitric Oxide Detectors Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.